Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | RAPGEF4 | Q8WZA2 | 6/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | CD44 | P16070 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4885560 | 0.76 | CYP3A4 (0.56) | CYP3A4CHRM1ALOX15TBXA2RADRA1A | |
| SCHEMBL4886977 | 0.75 | CYP3A4 (0.35) | CYP3A4 | |
| SCHEMBL2260986 | 0.73 | CYP3A4 (0.59) | CYP3A4CHRM1ALOX15MAOATBXA2R | |
| SCHEMBL31519176 | 0.73 | CYP3A4 (0.59) | CYP3A4CHRM1ALOX15MAOATBXA2R | |
| SCHEMBL1006177 | 0.70 | CYP3A4 (0.43) | CYP3A4CHRM1ALOX15MAOATBXA2R | |
| SCHEMBL31465325 | 0.70 | CYP3A4 (0.43) | CYP3A4CHRM1ALOX15MAOATBXA2R | |
| SCHEMBL4889558 | 0.70 | ALDH1A1 (0.36) | CYP3A4CHRM1TBXA2RRAPGEF4ALDH1A1 | |
| SCHEMBL8436944 | 0.70 | ALDH1A1 (0.39) | CYP3A4CHRM1ALOX15MAOATBXA2R | |
| SCHEMBL4885803 | 0.70 | CYP3A4 (0.41) | CYP3A4RAPGEF4SIRT1ALDH1A1 | |
| SCHEMBL4892232 | 0.70 | GRIN2D (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817318-B1 | STABILIZING METHOD AND STABILIZED COMPOSITION FOR ARYL BORON COMPOUNDS | NIPPON CATALYTIC CHEM IND (JP) | 2013-08-28 | — | — | EP | disclosed |
| US-20080154065-A1 | Stabilizing Method and Stabilized Composition for Aryl Boron Compounds | NIPPON SHOKUBAI CO., LTD. (JP) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080154065-A1 | Stabilizing Method and Stabilized Composition for Aryl Boron Compounds | AR, AHR, BCL6 | CYP3A4 2401/4885CHRM1 3430/4885ALOX15 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.